Page 9 - Controlled Trial News Today

/PRNewswire/ -- Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in...

/PRNewswire/ -- Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in...

Study may change the way we manage patients with moderate aortic stenosis and save lives

Press release content from Business Wire. The AP news staff was not involved in its creation.

BOOSTER.Photo taken on Aug. 23, 2021 shows Pfizer signage at Pfizer's World Headquarters in New York, United States. (Photo by Michael Nagle/Xinhua) WASHINGTON-Pfizer and BioNTech announced Thursday that a large-scale trial of their coronavirus disease 2019 (Covid-19) vaccine booster showed it restored full protection against the disease. In Phase 3 randomized, controlled trial, a Pfizer-BioNTech booster dose was administered to more than 10,000 individuals 16 years of age and older, who pre...

/PRNewswire/ -- Hansa on track to achieve key 2021 objectives: Agreements on funding obtained in three countries; HTA submissions in ten countries; and...

/PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented...

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, R...

-- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased

Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics, a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based plat...